MTOR and ovarian carcinoma: This novel therapeutic agent NVP-BEZ235, which targets both PI3K and mTOR, has been shown to inhibit cell growth of cisplatin-sensitive as well as cisplatin-resistant human ovarian carcinoma cell lines [73, 74].